171 related articles for article (PubMed ID: 30627554)
1. Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching.
Kim SH; Park EY; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Biomed Res Int; 2018; 2018():4307207. PubMed ID: 30627554
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
Pu XY; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
[TBL] [Abstract][Full Text] [Related]
3. Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.
Kang M; Jung JW; Oh JJ; Lee S; Hong SK; Lee SE; Byun SS
Clin Genitourin Cancer; 2016 Aug; 14(4):e363-9. PubMed ID: 27105723
[TBL] [Abstract][Full Text] [Related]
4. Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
Hu JC; Hung SC; Ou YC
Anticancer Res; 2017 Jun; 37(6):3143-3150. PubMed ID: 28551656
[TBL] [Abstract][Full Text] [Related]
5. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
6. Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
Kim SH; Park WS; Kim SH; Park B; Joo J; Lee GK; Joung JY; Seo HK; Chung J; Lee KH
PLoS One; 2016; 11(3):e0151646. PubMed ID: 26982980
[TBL] [Abstract][Full Text] [Related]
7. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
8. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant hormonal therapy in carcinoma of the prostate.
Lee HH; Warde P; Jewett MA
BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
[TBL] [Abstract][Full Text] [Related]
11. Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort.
Sun G; Liang Z; Jiang Y; Ma S; Chen S; Liu R
Curr Oncol; 2022 Nov; 29(11):8668-8676. PubMed ID: 36421336
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
Naiki T; Kawai N; Okamura T; Nagata D; Kojima Y; Akita H; Yasui T; Tozawa K; Kohri K
BMC Urol; 2012 Dec; 12():36. PubMed ID: 23249358
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
17. Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer.
Ceylan C; Tonyali S; Keles I
Kaohsiung J Med Sci; 2016 Oct; 32(10):514-517. PubMed ID: 27742035
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant hormonal therapy versus surgery alone for radical prostatectomy in high-risk prostate cancer patients].
Kobayashi M; Saito Y; Komaru A; Fukasawa S; Suyama T; Akakura K; Ichikawa T; Ueda T
Hinyokika Kiyo; 2013 Jul; 59(7):411-8. PubMed ID: 23945319
[TBL] [Abstract][Full Text] [Related]
19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
20. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]